论文部分内容阅读
目的:系统评价生脉注射液联合化疗治疗非小细胞肺癌的疗效。方法:计算机检索Pubmed、Cochrane library、EMbase、SCI、中国期刊全文数据库、中国生物医学文献数据库、万方数据库及维普数据库,并对纳入的文献进行严格的质量评价和Meta分析。结果:共纳入9项研究,合计585例患者。两组患者总有效率[OR=1.67,95%C(I1.20,2.33),P<0.01]、生活质量量表(KPS)评分增加发生率[OR=3.33,95%CI(2.27,4.88),P<0.01]、体质量增加发生率[OR=4.85,95%CI(2.85,8.24),P<0.01]、骨髓抑制发生率[OR=0.39,95%C(I0.27,0.56),P<0.01]、肝肾损害发生率[OR=0.31,95%C(I0.14,0.68),P<0.01]、胃肠道反应发生率[OR=0.49,95%C(I0.33,0.73),P<0.01]比较差异均有统计学意义,但总有效率分析纳入的研究可能存在发表偏倚。结论:生脉注射液联合化疗治疗非小细胞肺癌,在提高患者生存质量,降低化疗相关不良反应方面效果确切,且对化疗有协同增效作用,但尚需更多的研究加以证实。
Objective: To systematically evaluate the efficacy of Shengmai injection combined with chemotherapy in the treatment of non-small cell lung cancer. Methods: Computer search Pubmed, Cochrane library, EMbase, SCI, Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Wanfang Database and VIP Database, and the rigorous quality assessment and meta-analysis of the included literature. Results: A total of 9 studies were included with a total of 585 patients. The total effective rate of the two groups was [OR=1.67, 95%C(I1.20, 2.33), P<0.01], and the increase in the quality of life scale (KPS) score [OR=3.33, 95%CI(2.27,4.88). ), P<0.01], incidence of increased body mass [OR=4.85, 95% CI (2.85, 8.24), P<0.01], incidence of myelosuppression [OR=0.39, 95% C (I0.27, 0.56) , P<0.01], incidence of liver and kidney damage [OR=0.31, 95%C (I0.14, 0.68), P<0.01], incidence of gastrointestinal reactions [OR=0.49, 95% C (I 0.33 , 0.73), P<0.01] The difference was statistically significant, but the total efficiency analysis included in the study may be published biased. Conclusion: Shengmai injection combined with chemotherapy in the treatment of non-small cell lung cancer is effective in improving the quality of life of patients, reducing the adverse reactions related to chemotherapy, and has a synergistic effect on chemotherapy, but more studies are needed to confirm.